Skip to main contentSkip to navigationSkip to search


August 24, 2021

CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær presents the Interim Report First Half 2021 at HC Andersen Capital, 24 August 2021.

October 30, 2019

Curasight receives EPO patent notification with issue date 28 August 2019 and patent number 2928505

May 22, 2018

Curasight technology contribute to fluorescent tumours will vastly improve survival for people with cancer

March 1, 2018

Curasight have received US patent notification with issue date 6 February 2018 and patent number 9884131.

November 21, 2017

Curasight initiates new phase II study within Prostate Cancer for risk stratification

July 1, 2017

Ga-NOTA-AE105 (uTRACE®) included in a new book on “Novel PET Radiotracers with Potential Clinical Applications”.

April 1, 2017

Researcher from Curasight and Rigshospitalet publish review on uPAR-PET in prostate cancer.

March 1, 2017

Phase I study of our uPAR-PET tracer in the March issue of Journal of Nuclear Medicine

October 30, 2016

Our phase I study just published online in Journal of Nuclear Medicine

September 15, 2016

Curasight presents at BioPharm-America Conference in Boston.